Table 1

Association of Maspin expression to demographic, clinical, and pathological variables in 97 radical prostatectomy patients with no prior androgen ablation therapy

Variable	Total patients	Maspin expression			% Positive	P^a
Variable	Total patients			Negative	% Positive	P^a	Positive
Total	97	58	39	40.2
Age					0.317
<55	11	7	4	36.4
55–59	12	4	8	66.7
60–64	34	21	13	38.2
65–69	29	20	9	31.0
≥70	11	6	5	45.5
Race					0.121
African-American	22	10	12	54.6
Caucasian	75	48	27	36.0
WHO differentiation					0.050
Well	31	23	8	25.8
Moderate	32	18	14	43.8
Poor	34	17	17	50.0
WHO nuclear grade					0.108
I	37	25	12	32.4
II	58	33	25	43.1
III	2	0	2	100.0
Gleason sum					0.199
3–5	9	6	3	33.3
6	54	35	19	35.2
7	26	13	13	50.0
8–9	8	4	4	50.0
Pretreatment PSA					0.765
0–4	11	7	4	36.4
4.1–10.0	52	32	20	38.5
10.1–20.0	25	14	11	44.0
≥20.1	8	5	3	37.5
Unknown	1	0	1
Pathological stage					0.199
pT2	42	27	15	35.7
pT3	49	27	22	44.9
pT4	2	0	2	100.0
pTx	6	4	2

^a P for the Mantel-Haenszel χ² test for trend in the association between Maspin expression and the levels of the variable. Pretreatment PSA = unknown and pathological stage = pTx were not included as levels in the trend tests.